Screening of Genetic Polymorphisms of CYP3A4 and CYP3A5 Genes

다국어 초록 (Multilingual Abstract)

Given the CYP3A4 and CYP3A5’s impact on the efficacy of drugs, the genetic backgrounds of individuals and populations are regarded as an important factor to be considered in the prescription of personalized medicine. However, genetic studies with Korean population are relatively scarce compared to those with other populations. In this study, we aimed to identify CYP3A4/5 polymorphisms and compare the genotype distributions among five ethnicities. To identify CYP3A4/5 SNPs, we first performed direct sequencing with 288 DNA samples which consisted of 96 Koreans, 48 European-Americans, 48 African-Americans, 48 Han Chinese, and 48 Japanese. The direct sequencing identified 15 novel SNPs, as well as 42 known polymorphisms. We defined the genotype distributions, and compared the allele frequencies among five ethnicities. The results showed that minor allele frequencies of Korean population were similar with those of the Japanese and Han Chinese populations, whereas there were distinct differences from European-Americans or African-Americans. Among the pharmacogenetic markers, frequencies of CYP3A4*1B (rs2740574) and CYP3A5*3C (rs776742) in Asian groups were different from those in other populations. In addition, minor allele frequency of CYP3A4*18(rs28371759) was the highest in Korean population. Additional in silico analysis predicted that two novel non-synonymous SNPs in CYP3A5 (+27256C＞T, P389S and +31546T＞G, I488S) could alter protein structure. The frequency distributions of the identified polymorphisms in the present study may contribute to the expansion of pharmacogenetic knowledge.

참고문헌 (Reference)

1 Wrighton SA, "The human hepatic cytochromes P450 involved in drug metabolism" 22 : 1-21, 1992

2 Hustert E, "The genetic determinants of the CYP3A5 polymorphism" 11 : 773-779, 2001

3 Lee SJ, "The CYP3A4*18 allele, the most frequent coding variant in Asian populations, does not significantly affect the Midazolam disposition in heterozygous individuals" AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS 35 : 2095-2101, 2007

4 Kang YS, "The CYP3A4* 18 genotype in the cytochrome P450 3A4 gene, a rapid metabolizer of sex steroids, is associated with low bone mineral density" 85 : 312-318, 2009

5 Wrighton SA, "Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5(HLp3)" 38 : 207-213, 1990

6 Rostami-Hodjegan A, "Simulation and prediction of in vivo drug metabolism in human populations from in vitro data" 6 : 140-148, 2007

7 Kuehl P, "Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression" 27 : 383-391, 2001

8 Dennison JB, "Selective metabolism of vincristine in vitro by CYP3A5" 34 : 1317-1327, 2006

9 Wen S, "Screening of 12 SNPs of CYP3A4 in a Chinese population using oligonucleotide microarray" 8 : 411-416, 2004

10 Lee SJ, "Recombinant CYP3A4*17 is defective in metabolizing the hypertensive drug nifedipine, and the CYP3A4*17 allele may occur on the same chromosome as CYP3A5*3, representing a new putative defective CYP3A haplotype" 313 : 302-309, 2005

11 Rozen S, "Primer3 on the WWW for general users and for biologist programmers" 132 : 365-386, 2000

12 Hesselink DA, "Population pharmacokinetics of cyclosporine in kidney and heart transplant recipients and the influence of ethnicity and genetic polymorphisms in the MDR-1, CYP3A4, and CYP3A5 genes" 76 : 545-556, 2004

13 Ball SE, "Population distribution and effects on drug metabolism of a genetic variant in the 5' promoter region of CYP3A4" 66 : 288-294, 1999

14 Streetman DS, "Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes" 10 : 187-216, 2000

15 Tran A, "Pharmacokinetics and toxicity of docetaxel : role of CYP3A, MDR1, and GST polymorphisms" 79 : 570-580, 2006

16 Weinshilboum R, "Pharmacogenomics : bench to bedside" 3 : 739-748, 2004

17 Sim SC, "Pharmacogenomic biomarkers : new tools in current and future drug therapy" 32 : 72-81, 2011

18 Savonarola A, "Pharmacogenetics and pharmacogenomics : role of mutational analysis in anti-cancer targeted therapy" 12 : 277-286, 2012

19 MacPhee IA, "Pharmacogenetic biomarkers : cytochrome P450 3A5" 413 : 1312-1317, 2012

20 Kristyanto H, "Pharmacogenetic application in personalized cancer treatment" 42 : 109-115, 2010

21 Wacher VJ, "Overlapping substrate specificities and tissue distribution of cytochrome P450 3A and P-glycoprotein : implications for drug delivery and activity in cancer chemotherapy" 13 : 129-134, 1995

22 Hsieh KP, "Novel mutations of CYP3A4 in Chinese" 29 : 268-273, 2001

23 Watkins PB, "Noninvasive tests of CYP3A enzymes" 4 : 171-184, 1994

24 Lee AJ, "NADPHdependent metabolism of estrone by human liver microsomes" 300 : 838-849, 2002

25 Hall SD, "Molecular and physical mechanisms of first-pass extraction" 27 : 161-166, 1999

26 Amirimani B, "Increased transcriptional activity of the CYP3A4* 1B promoter variant" 42 : 299-305, 2003

27 Dai D, "Identification of variants of CYP3A4 and characterization of their abilities to metabolize testosterone and chlorpyrifos" 299 : 825-831, 2001

28 Barrett JC, "Haploview: analysis and visualization of LD and haplotype maps" 21 : 263-265, 2005

29 Gellner K, "Genomic organization of the human CYP3A locus : identification of a new, inducible CYP3A gene" 11 : 111-121, 2001

30 Ruzilawati AB, "Genetic polymorphisms of CYP3A4: CYP3A4*18 allele is found in five healthy Malaysian subjects" 383 : 158-162, 2007

31 Lamba JK, "Genetic contribution to variable human CYP3A-mediated metabolism" 64 : 256-269, 2012

32 Ozdemir V, "Evaluation of the genetic component of variability in CYP3A4 activity : a repeated drug administration method" 10 : 373-388, 2000

33 Seo T, "Effect of CYP3A5*3 on carbamazepine pharmacokinetics in Japanese patients with epilepsy" 79 : 509-510, 2006

34 Park PW, "Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients" BLACKWELL PUBLISHING 34 : 569-574, 2009

35 Sun H, "Dirlotapide as a model substrate to refine structure-based drug design strategies on CYP3A4-catalyzed metabolism" 22 : 371-376, 2012

36 Guengerich FP, "Cytochrome p450 and chemical toxicology" 21 : 70-83, 2008

37 McCune JS, "Contribution of CYP3A5 to hepatic and renal ifosfamide N-dechloroethylation" 33 : 1074-1081, 2005

38 Lee AJ, "Characterization of the NADPH-dependent metabolism of 17beta-estradiol to multiple metabolites by human liver microsomes and selectively expressed human cytochrome P450 3A4 and 3A5" 298 : 420-432, 2001

39 Walker AH, "Characterization of an allelic variant in the nifedipine-specific element of CYP3A4: ethnic distribution and implications for prostate cancer risk. Mutations in brief no. 191. Online" 12 : 289-, 1998

40 Hu YF, "CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population" 353 : 187-192, 2005

41 Min DI, "CYP3A5 polymorphism and the ethnic differences in cyclosporine pharmacokinetics in healthy subjects" 26 : 524-528, 2004

42 Elens L, "CYP3A4*22 : promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy" 14 : 47-62, 2013

43 Yamamoto T, "CYP3A4*18 : it is not rare allele in Japanese population" 18 : 267-268, 2003

44 Petros WP, "Associations between drug metabolism genotype, chemotherapy pharmacokinetics, and overall survival in patients with breast cancer" 23 : 6117-6125, 2005

45 Devlin B, "A comparison of linkage disequilibrium measures for fine-scale mapping" 29 : 311-322, 1995

46 Huang Z, "16Alpha-hydroxylation of estrone by human cytochrome P4503A4/5" 19 : 867-872, 1998